Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
78.22 USD | -0.60% | -2.64% | +0.55% |
09:34pm | Sector Update: Financial Stocks Easing Late Afternoon | MT |
07:32pm | Sector Update: Financial Stocks Sliding Friday Afternoon | MT |
Financials (USD)
Sales 2024 * | 32,176 M | Sales 2025 * | 33,640 M | Capitalization | 105 B |
---|---|---|---|---|---|
Net income 2024 * | 4,483 M | Net income 2025 * | 5,153 M | EV / Sales 2024 * | 3,90x |
Net Debt 2024 * | 20,676 M | Net Debt 2025 * | 18,775 M | EV / Sales 2025 * | 3,67x |
P/E ratio 2024 * | 23,1x | P/E ratio 2025 * | 20,0x | Employees | - |
Yield 2024 * | 3,53% | Yield 2025 * | 3,61% | Free-Float | 99.83% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
1 day | -0.67% | ||
1 week | -2.57% | ||
Current month | -4.04% | ||
1 month | -4.71% | ||
3 months | -9.87% | ||
6 months | -1.09% | ||
Current year | +0.63% |
1 week
77.44
80.31

1 month
77.44
83.64

Current year
76.02
92.02

1 year
75.77
92.02

3 years
75.77
135.89

5 years
72.13
135.89

10 years
52.44
135.89

Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.07% | 30 M$ | +5.20% | - |
Date | Price | Change | Volume |
---|---|---|---|
23-09-29 | 78.16 | -0.68% | 3 775 664 |
23-09-28 | 78.69 | +0.60% | 5,354,099 |
23-09-27 | 78.22 | -0.92% | 7,418,382 |
23-09-26 | 78.95 | -1.28% | 5,166,964 |
23-09-25 | 79.97 | -0.37% | 3,799,682 |
Delayed Quote Nyse, September 29, 2023 at 03:24 pm EDT
More quotes
Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows:
- general and minimally invasive surgery (28.8%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.;
- cardiac rhythm management (18.6%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.;
- vascular diseases and cardiac surgery (17.4%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.;
- spinal disorders (14.1%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity;
- neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.2%);
- diabetes management (7.4%): internal and external glycemia monitoring systems and insulin pumps;
- neurological disorders (5.5%): neurostimulation and pumped medication administration products, diagnostic tools, etc.
Net sales are distributed geographically as follows: Ireland (0.3%), the United States (50.9%) and other (48.8%).
Calendar
Trading Rating :
Investor Rating :
ESG Refinitiv :
C
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
78.69USD
Average target price
94.65USD
Spread / Average Target
+20.28%
EPS Revisions
1st Jan change | Capi. (M$) | |
---|---|---|
+0.63% | 105 B $ | |
-27.55% | 223 M $ | |
-45.01% | 520 M $ | |
-41.76% | 302 M $ | |
+71.43% | 67 M $ | |
+10.92% | 2 859 M $ | |
-52.78% | 51 M $ | |
+8.21% | 50 M $ | |
-52.76% | 1 191 M $ | |
-3.77% | 290 M $ |